Inflammatory bowel disease (IBD) and irritable bowel syndrome (IBS) are two chronic conditions associated with diarrhea and abdominal pain, and these symptoms are among the most common reasons that patients seek medical advice. [ LEARN MORE]
5 to 7 days
Click any analyte name for additional clinical information, including reference ranges, specimen collection, stability and rejection criteria.
List price applies when filing with insurance or Medicare, or when billing a patient directly. Prompt payment pricing applies when billing to a physician account or prepayment is received with the test.
Doctor's Data offers profiles containing multiple analytes. *Multiple analytes may be billed under a single CPT code. Many analytes can be ordered individually. Pricing may vary. Click on a specific analyte for more information or read our detailed billing and payment policies.
The CPT codes listed on our website are for informational purposes only. This information is our interpretation of CPT coding requirements and may not necessarily be correct. You are advised to consult the CPT Coding Manual published by the American Medical Association. Doctor's Data, Inc. takes no responsibility for billing errors due to your use of any CPT information from our website.
Sign in at the top of any page to view pricing and order tests. Or click here to create an account. You may also contact us for assistance placing an order.
Fecal lactoferrin is a biomarker of serious gastrointestinal inflammation. Fecal lactoferrin is elevated in association with Inflammatory Bowel Disease (IBD) such as Ulcerative Colitis (UC) or Crohn's Disease (CD), but NOT Irritable Bowel Syndrome (IBS). Therefore, assessment of fecal lactoferrin levels enables distinction between IBD and non-inflammatory IBS. Such distinction is critical because, although both IBD and IBS may share some common symptoms such as diarrhea, abdominal cramping and weight loss, the diseases are treated quite differently. IBD may become life threatening, requires life-long treatment and possibly surgery. In contrast, IBS is often effectively treated with dietary restrictions, stress reduction and medication.
Gastrointestinal inflammation associated with IBD is associated with increased infiltration of activated neutrophils into the mucosa and increased release of lactoferrin into the gut. Patients with inflammation of the GI tract, such as IBD (but not IBS), exhibit elevated lactoferrin concentrations in the feces.
Clinical studies have shown that fecal lactoferrin levels of healthy persons are similar to IBS patients, but markedly increased in patients with active IBD. Patients with IBD oscillate between active and inactive disease states, and fecal lactoferrin levels increase 2-3 weeks prior to onset of clinical symptoms. During remission and effective treatment, fecal lactoferrin decreases significantly. Therefore disease activity, and efficacy of treatment can be monitored by following fecal lactoferrin levels.